In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-06-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00070-13PMID 23774435PMCID PMC3754355
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VNI cures acute and chronic experimental Chagas disease.

  2013cited by this paper
• In Vitro and In Vivo Investigation of the Efficacy of Arylimidamide DB1831 and Its Mesylated Salt Form - DB1965 - against Trypanosoma cruzi Infection

  2012cited by this paper
• CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds.

  2012cited by this paper
• Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib

  2012cited by this paper
• Structural basis for conservation in the CYP51 family.

  2011cited by this paper
• Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis.

  2011cited by this paper
• Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

  2011cited by this paper
• Vaccine development against Trypanosoma cruzi and Chagas disease.

  2011cited by this paper
• Infectious diseases. Drug developers finally take aim at a neglected disease.

  2011cited by this paper
• A novel triazolic naphthofuranquinone induces autophagy in reservosomes and impairment of mitosis in Trypanosoma cruzi

  2011cited by this paper
• Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies

  2011cited by this paper
• Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas' Disease Treatment

  2010cited by this paper
• The biological in vitro effect and selectivity of aromatic dicationic compounds on Trypanosoma cruzi.

  2010cited by this paper
• Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

  2010cited by this paper
• In vitro and in vivo experimental models for drug screening and development for Chagas disease.

  2010cited by this paper
• Effects of Ravuconazole Treatment on Parasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruzi

  2010cited by this paper
• Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi*

  2010cited by this paper
• Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections*♦

  2009cited by this paper
• Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies.

  2009cited by this paper
• A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI.

  2009cited by this paper
• Ergosterol biosynthesis and drug development for Chagas disease.

  2009cited by this paper
• Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions

  2008cited by this paper
• CYP51: A Major Drug Target in the Cytochrome P450 Superfamily

  2008cited by this paper
• Activity of "reversed" diamidines against Trypanosoma cruzi "in vitro".

  2007cited by this paper
• Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

  2007cited by this paper
• CYP51 from Trypanosoma cruzi

  2006cited by this paper
• Antiparasitic activity of aromatic diamidines is related to apoptosis-like death in Trypanosoma cruzi

  2006cited by this paper
• The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease

  2005cited by this paper
• Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma cruzi and Leishmania amazonensis.

  2004cited by this paper
• History of the development of azole derivatives.

  2004cited by this paper
• Inhibitors of vitamin D hydroxylases: Structure–activity relationships

  2003cited by this paper
• In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease.

  2003cited by this paper
• Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa.

  2003cited by this paper
• OECD GUIDELINE FOR TESTING OF CHEMICALS

  2002cited by this paper
• Modulation induced by estradiol in the acute phase of Trypanosoma cruzi infection in mice

  2001cited by this paper
• Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts

  2000cited by this paper
• Treatment of chronic Chagas' disease with itraconazole and allopurinol.

  1998cited by this paper
• Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox.

  1998cited by this paper
• Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples from chronic chagasic patients in a rural endemic area.

  1995cited by this paper
• Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi

  1988cited by this paper
• Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.

  1987cited by this paper
• Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes.

  1986cited by this paper
• Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.

  1985cited by this paper
• Revised methods for the Salmonella mutagenicity test.

  1983cited by this paper
• Cytogenetic activities of a triazine herbicide in root tips of Allium cepa and Vicia faba

  1983cited by this paper
• Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi.

  1981cited by this paper
• GROWTH AND DIFFERENTIATION IN TRYPANOSOMA CRUZI. I. ORIGIN OF METACYCLIC TRYPANOSOMES IN LIQUID MEDIA.

  1964cited by this paper

• Heme limitation induces LHR2, an essential gene for Leishmania pathogenesis.

  2026cites this paper
• Targeting nitroreductases for selective drug activation: therapeutic perspectives in neglected diseases and tuberculosis.

  2025cites this paper
• Combating Drug‐Resistant Protozoal Infections: A Review of Emerging Therapeutics

  2025influential citation
• Treatment options for Chagas Disease: a systematic review and meta-analysis applied to the preclinical studies using animal models

  2024cites this paper
• Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

  2024cites this paper
• Oral Pyronaridine Tetraphosphate Reduces Tissue Presence of Parasites in a Mouse Model of Chagas Disease

  2024cites this paper
• Treatment options applied to the preclinical studies using animal models for Chagas Disease: a systematic review and meta-analysis

  2024cites this paper
• Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain

  2023cites this paper
• Impact of Laboratory-Adapted Intracellular Trypanosoma cruzi Strains on the Activity Profiles of Compounds with Anti-T. cruzi Activity

  2023cites this paper
• Exploring Synthetic Dihydrobenzofuran and Benzofuran Neolignans as Antiprotozoal Agents against Trypanosoma cruzi

  2023cites this paper
• Antiplasmodial, Trypanocidal, and Genotoxicity In Vitro Assessment of New Hybrid α,α-Difluorophenylacetamide-statin Derivatives

  2023cites this paper
• In vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsule devices with host cardiomyoblasts and Trypanosoma cruzi-infective forms

  2022cites this paper
• Perspectives for a new drug candidate for Chagas disease therapy

  2022cites this paper
• Revisiting Pyrazolo[3,4-d]pyrimidine Nucleosides as Anti-Trypanosoma cruzi and Antileishmanial Agents.

  2021cites this paper
• Review on Experimental Treatment Strategies Against Trypanosoma cruzi

  2021cites this paper
• The role of imidazole and benzimidazole heterocycles in Chagas disease: A review.

  2020cites this paper
• Research Models in Biomedical Sciences: Advantages and Limitations

  2020cites this paper
• Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids.

  2020cites this paper
• Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity

  2020cites this paper
• Activity profile of two 5-nitroindazole derivatives over the moderately drug-resistant Trypanosoma cruzi Y strain (DTU TcII): in vitro and in vivo studies

  2020cites this paper
• Why hasn’t there been more progress in new Chagas disease drug discovery?

  2020cites this paper
• Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs

  2020cites this paper
• Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery

  2020cites this paper
• Phenyldihydropyrazolones as Novel Lead Compounds Against Trypanosoma cruzi

  2019cites this paper
• Advances in preclinical approaches to Chagas disease drug discovery

  2019cites this paper
• Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease

  2019cites this paper
• Discovery of pyrrolo[2,3-b]pyridine (1,7-dideazapurine) nucleoside analogues as anti-Trypanosoma cruzi agents.

  2019cites this paper
• The effect of Benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.

  2019cites this paper
• Current trends in the pharmacological management of Chagas disease

  2019cites this paper
• Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.

  2019cites this paper
• Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi

  2019cites this paper
• Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity

  2018cites this paper
• Impact of autologous whole blood administration upon experimental mouse models of acute Trypanosoma cruzi infection

  2018cites this paper
• Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi

  2018cites this paper
• Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.

  2018cites this paper
• Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

  2018cites this paper
• Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.

  2018cites this paper
• Antichagasic, Leishmanicidal, and Trichomonacidal Activity of 2‐Benzyl‐5‐nitroindazole‐Derived Amines

  2018cites this paper
• Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice

  2018cites this paper
• Benznidazol e Posaconazol na Eliminação de Parasitas em Portadores Assintomáticos de T. Cruzi. O Ensaio clinico STOP-CHAGAS

  2018cites this paper
• Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.

  2018cites this paper
• A convergent, scalable and stereoselective synthesis of azole CYP51 inhibitors.

  2017cites this paper
• Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain

  2017cites this paper
• Ergosterol isolated from the basidiomycete Pleurotus salmoneostramineus affects Trypanosoma cruzi plasma membrane and mitochondria

  2017cites this paper
• Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.

  2017cites this paper
• Drug Resistance Assays for Parasitic Diseases

  2017cites this paper
• Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers The STOP-CHAGAS Trial

  2017cites this paper
• Novas abordagens na pesquisa de alvos terapêuticos frente à infecção por Trypanosoma cruzi

  2016cites this paper
• Assessing anti-T. cruzi candidates in vitro for sterile cidality

  2016cites this paper
• Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents.

  2016cites this paper
• Current drug therapy and pharmaceutical challenges for Chagas disease.

  2016cites this paper
• Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.

  2016cites this paper
• Ensaios biológicos in vitro e in vivo de novos compostos sintéticos sobre infecção por Trypanosoma cruzi

  2015cites this paper
• Exploring the potential activity spectrum of two 5-nitroindazolinone prototypes on different Trypanosoma cruzi strains

  2015cites this paper
• Structure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs*

  2015cites this paper
• Chagas Disease Drug Discovery

  2015cites this paper
• Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

  2015cites this paper
• A new era for chagas disease drug discovery?

  2015cites this paper
• Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.

  2015cites this paper
• Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

  2015cites this paper
• Targeting sterol metabolism for the development of antileishmanials.

  2015cites this paper
• Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection

  2015cites this paper
• Atividade ectonucleotidásica e localização celular das NTPDases nos tripanosomatídeos Trypanosoma cruzi e Leishmania tarentolae

  2015cites this paper
• Drug Strategies Targeting CYP51 in Neglected Tropical Diseases

  2014cites this paper
• In Vitro and In Vivo Biological Effects of Novel Arylimidamide Derivatives against Trypanosoma cruzi

  2014cites this paper
• Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51

  2014cites this paper
• Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition

  2014cites this paper
• Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.

  2014cites this paper
• In Vitro and In Vivo Studies of the Biological Activity of Novel Arylimidamides against Trypanosoma cruzi

  2014cites this paper
• Structural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition

  2014cites this paper
• Therapeutical approaches under investigation for treatment of Chagas disease

  2014cites this paper
• Potential new clinical therapies for Chagas disease

  2014cites this paper
• Sterol Biosynthesis Is Required for Heat Resistance but Not Extracellular Survival in Leishmania

  2014cites this paper
• Avaliação do efeito do derivado de β-lapachona R72 em formas tripomastigotas de Trypanosoma cruzi e na infecção de macrófagos pelo T. cruzi in vitro

  2014cites this paper
• T. cruzi CYP51 complexes with UDO and UDD Complexes of Trypanosoma cruzi sterol 14a-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: Structural basis for pathogen-selectivity*

  2013cites this paper
• Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease

  2013cites this paper
• Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

  2013cites this paper
• Trypanocidal Activity of Marine Natural Products

  2013cites this paper
• In vitro and in vivo activity of the chloroaryl-substituted imidazole viniconazole against Trypanosoma cruzi

  2013cites this paper
• Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease

  2013cites this paper